The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Dose optimization portion of the APEX trial investigating bezuclastinib in patients with AdvSM
In this video, Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, presents the findings of the dose optimization portion of the ongoing APEX trial (NCT04996875), which is assessing bezuclastinib in patients with advanced systemic mastocytosis (AdvSM). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So systemic mastocytosis is a rare disease. Patients with advanced form of the disease have a life-threatening and life-shortening illness. It’s driven by KIT, specifically the D816V, which is a canonical mutation in systemic mastocytosis. Bezuclastinib is a new-in-class specific KIT inhibitor, and it was shown in this dose-finding study that the 100 milligram twice daily dose is the optimal dose going forward...
So systemic mastocytosis is a rare disease. Patients with advanced form of the disease have a life-threatening and life-shortening illness. It’s driven by KIT, specifically the D816V, which is a canonical mutation in systemic mastocytosis. Bezuclastinib is a new-in-class specific KIT inhibitor, and it was shown in this dose-finding study that the 100 milligram twice daily dose is the optimal dose going forward. There’s been a slight formulation change so it’s been reduced to 150 milligrams once a day but we showed that the bezuclastinib is safe and effective and leads to really profound reduction in mast cell burden and improved progression-free survival.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen, Autolus, Blueprint, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, Takeda: Consultancy; Mt Sinai MPN Consortium: Other: Mt Sinai MPN Consortium; Daiichi-Sankyo, Fibrogen: Other: DSMB; AbbVie, Blueprint, GlycoMimetics, Novartis: Research Funding; Dana-Farber Cancer Institute: Current Employment.
